Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
Rhea-AI Summary
Immuneering (Nasdaq: IMRX) reported second quarter 2026 results and business updates, highlighting its lead Deep Cyclic Inhibitor, atebimetinib. In a single-arm Phase 2a trial in first-line metastatic pancreatic cancer, atebimetinib plus modified gemcitabine/nab-paclitaxel showed a 17.3 month median overall survival in 55 patients, with 84% of evaluable patients weight stable or gaining weight at three months and limited high-grade treatment-related adverse event categories. A pivotal global Phase 3 trial, MAPKeeper 301, is underway with patients dosed and over 30 sites posted.
Immuneering ended Q2 2026 with $182.7 million in cash, cash equivalents and marketable securities and expects its cash runway to extend into 2029. Q2 R&D expenses were $14.0 million and G&A expenses $5.0 million, leading to a net loss of $17.3 million, or $0.27 per share.
Positive
- $182.7 million cash and securities at June 30, 2026; runway into 2029
- Phase 3 MAPKeeper 301 pancreatic cancer trial actively dosing patients at 30+ sites
- Phase 2a pancreatic study median overall survival 17.3 months in 55 patients
- 84% of evaluable Phase 2a patients weight stable or gaining at 3 months
- Q2 2026 interest income rose to $1.1 million, supporting total other income
- New CFO with prior senior finance and corporate development experience appointed
Negative
- Q2 2026 net loss increased to $17.3 million from $14.4 million year over year
- Q2 2026 R&D expenses rose to $14.0 million from $10.5 million
- Cash, cash equivalents and marketable securities declined from $217.0 million to $182.7 million since year-end 2025
- Accumulated deficit widened to $311.1 million as of June 30, 2026
News Explained
The release adds a dated development schedule: the first patient in the Phase 2 atebimetinib-plus-cemiplimab trial is planned for the second half of 2026, additional preclinical data are planned for the fourth quarter of 2026, IND-enabling studies for the next candidate are planned for mid-2027, preliminary Phase 2 data are expected in late 2027, and MAPKeeper 301 topline data are expected in mid-2028.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 15 | Q1 earnings report | Positive | +0.4% | Cash runway into 2029 and planned Phase 3 dosing supported the quarterly update. |
| Mar 06 | FY2025 earnings report | Positive | +7.0% | Phase 2a survival data, FDA and EMA alignment, and cash runway into 2029. |
| Nov 12 | Q3 earnings report | Positive | -2.6% | Clinical progress and financing increased reported resources while shares declined. |
| Aug 13 | Q2 earnings report | Positive | -5.6% | Strong survival data and patent progress coincided with a negative price reaction. |
| May 05 | Q1 earnings report | Positive | -4.8% | Clinical updates and financing progress coincided with a negative price reaction. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Earnings events produced mixed reactions: two aligned positive moves and three divergences despite positive clinical or financial updates.
Key Terms
overall survival medical
ctDNA medical
cachexia medical
open-label medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- 17.3 month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib in combination with chemotherapy, reported in oral presentation at ASCO Annual Meeting on June 1 -
- Phase 3 MAPKeeper 301 trial is underway, with patients being dosed and over 30 study locations posted to date -
- Peer-reviewed publication in Cancer Research details atebimetinib’s broad, durable preclinical activity, and favorable tolerability across RAS- and RAF-mutant tumors, along with preservation of body mass -
- Ended Q2 2026 with
NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today reported financial results for the second quarter ended June 30, 2026, and provided business updates.
“At a time when first-line pancreatic cancer patients finally have treatment options, the 17.3 month median overall survival reported at ASCO for atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in our single-arm Phase 2a study stands out as potentially best-in-class. Equally important in our Phase 2a data presented at ASCO is that
Recent Corporate Highlights:
- Dosing patients in the Company’s pivotal Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line pancreatic cancer. In June, Immuneering announced it had dosed the first patient in MAPKeeper 301, a global, randomized, open-label pivotal Phase 3 clinical trial evaluating atebimetinib + mGnP in first-line metastatic pancreatic cancer patients.
- Presented compelling Phase 2a data at the ASCO 2026 Annual Meeting, demonstrating 17.3 month median overall survival and a favorable tolerability profile in 55 first-line pancreatic cancer patients, together with
84% of evaluable patients weight stable or gaining weight at 3 months. The Phase 2a trial is evaluating atebimetinib in combination with mGnP with results reported as of an April 24, 2026 data cutoff. - Appointed Andrew Gengos as Chief Financial Officer. In June, Immuneering announced the appointment of Andrew Gengos as Chief Financial Officer. Mr. Gengos most recently served as Chief Financial Officer and Head of Corporate Development at Terns Pharmaceuticals, which Merck & Co., Inc. acquired for
$6.7 billion . Mr. Gengos will oversee financial strategy, capital allocation, investor relations, business development, and corporate development activities. - Published new findings in Cancer Research detailing atebimetinib’s broad, durable preclinical activity and favorable tolerability across RAS- and RAF-mutant tumors via Deep Cyclic Inhibition. In July, Immuneering announced the publication of an article in Cancer Research, a leading peer-reviewed journal of the American Association for Cancer Research, characterizing the differentiated mechanism and broad preclinical activity of atebimetinib. The article, “Dual-MEK Inhibitor Atebimetinib Displays Broad Activity in RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition and Resisting RAF-Bypass,” reports that atebimetinib demonstrated broad antitumor activity across RAS- and RAF-mutant models while resisting RAF-mediated bypass signaling, a key mechanism associated with resistance to other MEK inhibitors. Atebimetinib’s ability to preserve body mass in a preclinical model of cancer cachexia was also highlighted in the article.
- Presented Genetic Data at AACR demonstrating mechanism to improve durability and survival, supporting use of atebimetinib in first-line pancreatic cancer and beyond. In April, Immuneering presented new genetic data in a poster presentation demonstrating a key mechanism that may improve durability and survival, supporting the use of atebimetinib as a first-line treatment in pancreatic cancer and beyond. The circulating tumor DNA (ctDNA) data from 123 atebimetinib-treated patients showed that acquired MAPK pathway alterations were rarely seen. These findings suggest that Deep Cyclic Inhibitors have the potential to overcome the limitations of conventional MAPK inhibition and provide a more sustained clinical benefit for patients, while potentially preserving sensitivity to subsequent treatments.
Anticipated Upcoming Milestones
- 2H 2026: Dose the first patient in Phase 2 trial of atebimetinib + anti-PD-1 (cemiplimab) in non-small cell lung cancer, with a preliminary data readout expected in late-2027.
- Q4 2026: Additional preclinical data of atebimetinib in combination with anti-PD-1 in non-small cell lung cancer.
- Mid-2027: Begin IND-enabling studies for our next DCI product candidate program.
- Mid-2028: Topline data readout from the MAPKeeper 301 trial.
Second Quarter 2026 Financial Highlights
Cash Position: Cash, cash equivalents and marketable securities as of June 30, 2026 were
Research and Development (R&D) Expenses: R&D expenses for the second quarter of 2026 were
General and Administrative (G&A) Expenses: G&A expenses for the second quarter of 2026 were
Net Loss: Net loss attributable to common stockholders was
2026 Financial Guidance
Based on cash, cash equivalents and marketable securities as of June 30, 2026, and current operating plans, the Company expects its cash runway to be sufficient to fund operations into 2029.
About Immuneering Corporation
Immuneering is a late-stage clinical oncology company dedicated to keeping cancer patients alive and helping them thrive, with an initial focus on patients with RAS, RAF, and other MAPK-driven cancers. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors, designed to improve overall survival by three mechanisms: shrinking tumors durably with less resistance, preserving body mass by countering cachexia, and minimizing side effects to maximize performance status and combinability. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve survival across many cancer indications. The Company is conducting a global randomized pivotal trial, MAPKeeper 301, evaluating atebimetinib in combination with chemotherapy in first-line pancreatic cancer patients. The Company’s development pipeline also includes additional combination opportunities and preclinical stage programs. For more information, please visit www.immuneering.com.
Forward-Looking Statements
This press release contains forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding: the treatment potential of atebimetinib, alone or in combination with other agents to treat cancer, including modified Gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer and its potential to deliver overall survival with both durability and tolerability; the timing of dosing and preliminary readout of the planned Phase 2 lung cancer trial and the Phase 3 topline readout of the MAPKeeper 301 trial; the timing of beginning IND-enabling studies in a second DCI program; our operating plans and anticipated cash runway, and the potential ability of the three design mechanisms of atebimetinib to shrink tumors durably, improve overall survival and overcome the limitations of conventional MAPK inhibition and provide a more sustained clinical benefit for patients.
These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we are a late-stage clinical oncology company with a limited operating history and have not completed any registrational clinical trials; we have incurred significant losses, are not currently profitable and may never become profitable; limitations on our cash runway and potential increases in expenditures; our need for additional funding; our unproven approach to therapeutic intervention; our ability to address regulatory questions and changing regulatory standards, and the uncertainties relating to regulatory filings, reviews and approvals; the lengthy, expensive, and uncertain process of clinical drug development, including the uncertainty of whether positive preclinical or early clinical efficacy and safety results are confirmed in later-stage trials, potential delays in activation of trial sites or enrollment of trial participants, or failure to obtain regulatory approvals; our reliance on third parties and collaborators to conduct our clinical trials, manufacture our product candidates, and develop and commercialize our product candidates, if approved; failure to compete successfully against other drug companies; protection of our proprietary technology and the confidentiality of our trade secrets; potential lawsuits for, or claims of, infringement of third-party intellectual property or challenges to the ownership of our intellectual property; our patents being found invalid or unenforceable; costs and resources of operating as a public company; and unfavorable or no analyst research or reports.
These and other important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the period ended June 30, 2026, and our other reports filed with the U.S. Securities and Exchange Commission, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, except as required by law, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor Contact:
Laurence Watts
New Street Investor Relations
laurence@newstreetir.com
Media Contact:
David Caouette
dcaouette@immuneering.com
| IMMUNEERING CORPORATION | |||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS | |||||||||||||||
| (Unaudited) | |||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Operating expenses | |||||||||||||||
| Research and development | $ | 13,996,647 | $ | 10,454,160 | $ | 24,641,869 | $ | 21,925,852 | |||||||
| General and administrative | 4,996,444 | 4,296,417 | 9,678,939 | 8,302,059 | |||||||||||
| Amortization of intangible asset | 7,317 | 7,317 | 14,633 | 14,633 | |||||||||||
| Total operating expenses | 19,000,408 | 14,757,894 | 34,335,441 | 30,242,544 | |||||||||||
| Loss from operations | (19,000,408 | ) | (14,757,894 | ) | (34,335,441 | ) | (30,242,544 | ) | |||||||
| Other income (expense) | |||||||||||||||
| Interest income | 1,082,784 | 324,013 | 2,443,188 | 762,532 | |||||||||||
| Other income, net | 647,197 | — | 1,160,931 | — | |||||||||||
| Net loss | $ | (17,270,427 | ) | $ | (14,433,881 | ) | $ | (30,731,322 | ) | $ | (29,480,012 | ) | |||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.27 | ) | $ | (0.40 | ) | $ | (0.48 | ) | $ | (0.82 | ) | |||
| Weighted-average common shares outstanding, basic and diluted | 64,697,219 | 35,985,878 | 64,678,120 | 35,759,026 | |||||||||||
| Other comprehensive loss: | |||||||||||||||
| Unrealized loss from marketable securities | (165,235 | ) | — | (487,572 | ) | — | |||||||||
| Comprehensive Loss | $ | (17,435,662 | ) | $ | (14,433,881 | ) | $ | (31,218,894 | ) | $ | (29,480,012 | ) | |||
| IMMUNEERING CORPORATION | |||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
| (Unaudited) | |||||||
| June 30, 2026 | December 31, 2025 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 41,324,682 | $ | 128,645,025 | |||
| Marketable securities | 108,575,637 | 44,186,244 | |||||
| Prepaids and other current assets | 8,090,186 | 3,414,685 | |||||
| Total current assets | 157,990,505 | 176,245,954 | |||||
| Marketable securities, non-current | 32,773,479 | 44,183,186 | |||||
| Property and equipment, net | 879,922 | 938,481 | |||||
| Goodwill | 6,690,431 | 6,690,431 | |||||
| Intangible asset, net | 306,513 | 321,147 | |||||
| Right-of-use assets | 3,136,353 | 3,322,249 | |||||
| Other assets | 278,124 | 283,562 | |||||
| Total assets | $ | 202,055,327 | $ | 231,985,010 | |||
| Liabilities and Stockholders' Equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 3,377,359 | $ | 1,542,737 | |||
| Accrued expenses | 4,094,874 | 7,842,367 | |||||
| Other liabilities | 214,461 | 291,513 | |||||
| Lease liabilities | 428,962 | 397,104 | |||||
| Total current liabilities | 8,115,656 | 10,073,721 | |||||
| Long-term liabilities: | |||||||
| Lease liabilities, net of current portion | 3,204,645 | 3,427,321 | |||||
| Total liabilities | 11,320,301 | 13,501,042 | |||||
| Commitments and contingencies | |||||||
| Stockholders’ equity: | |||||||
| Preferred stock, | — | — | |||||
| Class A common stock, | 64,697 | 64,648 | |||||
| Class B common stock, | — | — | |||||
| Additional paid-in capital | 502,127,975 | 498,658,072 | |||||
| Accumulated other comprehensive income (loss) | (406,240 | ) | 81,332 | ||||
| Accumulated deficit | (311,051,406 | ) | (280,320,084 | ) | |||
| Total stockholders' equity | 190,735,026 | 218,483,968 | |||||
| Total liabilities and stockholders' equity | $ | 202,055,327 | $ | 231,985,010 | |||
